HDAd6/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells
Molecular Therapy - Methods & Clinical Development · 2023-06 · 29 · 213-226
DOI: 10.1016/j.omtm.2023.03.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy - Methods & Clinical Development, 2023-06. Verfasst von Hongjie Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Department of Medicine, Division of Medical Genetics, Seattle, WA 98195, USA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
In previous studies, we achieved safe and efficient in vivo hematopoietic stem cell (HSC) transduction in mobilized mice and macaques with intravenously injected helper-dependent adenovirus HDAd5/35++ vectors. These vectors are derivatives of serotype Ad5-containing CD46-affinity enhanced Ad35 fiber knob domains. Considering the impact of anti-Ad5/HDAd5/35++ neutralizing serum antibodies present in the human population, we generated HSC-retargeted HDAd6/35++ vectors derived from serotype 6. We found a lower prevalence and titers of serum anti-HDAd6/35++ in human samples compared with HDAd5/35++. HDAd6/35++ vectors efficiently transduced human and rhesus CD34+ cells in vitro. Intravenous injection of HDAd5/35++-GFP or HDAd6/35++-GFP vectors after G-CSF/AMD3100 mobilization of mice with established human hematopoiesis or human CD46 transgenic mice resulted in comparable GFP marking rates in HSCs in the bone marrow and spleen. In long-term in vivo HSC transduction and selection studies with integrating vectors, stable GFP expression in >75% of PBMCs was show for both vectors. In contrast with HDAd5/35++, undesired transduction of hepatocytes was minimal with HDAd6/35++. Furthermore, HDAd6/35++ allowed for efficient in vivo HSC transduction in Ad5-pre-immune mice. These features, together with the straightforward production of HDAd6/35++ vectors at high yield, make this new HDAd vector platform attractive for clinical translation of the in vivo approach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Washington, Department of Medicine, Division of Medical Genetics, Seattle, WA 98195, USA.
- Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, 58453 Witten, Germany.
- University of Washington, Department of Laboratory Medicine & Pathology and Lab, Seattle, WA 98195, USA.
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- NIDDK NIH HHS
- Bill and Melinda Gates Foundation
- National Institutes of Health
- NHLBI
Zitieren
APA
Wang, H., Georgakopoulou, A., Zhang, W., Kim, J., Gil, S., Ehrhardt, A., & Lieber, A. (2023). HDAd6/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells. Molecular Therapy - Methods & Clinical Development, 29, 213-226. https://doi.org/10.1016/j.omtm.2023.03.008
Vancouver
Wang H, Georgakopoulou A, Zhang W, Kim J, Gil S, Ehrhardt A, et al. HDAd6/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells. Molecular Therapy - Methods & Clinical Development. 2023;29:213-226. doi:10.1016/j.omtm.2023.03.008
BibTeX
@article{Wang2023,
author = {Wang, Hongjie and Georgakopoulou, Aphrodite and Zhang, Wenli and Kim, Jiho and Gil, Sucheol and Ehrhardt, Anja and Lieber, André},
title = {HDAd6/35++ - A new helper-dependent adenovirus vector platform for in vivo transduction of hematopoietic stem cells},
journal = {Molecular Therapy - Methods & Clinical Development},
year = {2023},
volume = {29},
pages = {213--226},
doi = {10.1016/j.omtm.2023.03.008}
}
EUVIMED